PREVDUO
Clinical safety rating
cautionComprehensive clinical and safety monograph for PREVDUO (PREVDUO).
Prevduo (doxycycline hyclate and omadacycline) is a combination of two tetracycline antibiotics. Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex. Omadacycline, a aminomethylcycline, also binds to the 30S subunit but overcomes common tetracycline resistance mechanisms (e.g., efflux pumps, ribosomal protection proteins).
| Metabolism | Doxycycline is partially metabolized in the liver via glucuronidation and other pathways; excreted in feces and urine. Omadacycline is not significantly metabolized; primarily eliminated unchanged in feces and urine. |
| Excretion | Renal: 70% unchanged; fecal: 20% (biliary); 10% metabolized |
| Half-life | Terminal half-life 9-12 hours (prolonged in renal impairment, clinical monitoring recommended) |
| Protein binding | 85-90% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 1.5 L/kg (extensive distribution; suggests high tissue penetration) |
| Bioavailability | Oral: 60-70% (first-pass metabolism; food reduces absorption by 20%) |
| Onset of Action | Oral: 1-2 hours; Intravenous: 5-10 minutes |
| Duration of Action | 12-24 hours (dose-dependent; therapeutic levels maintained for 12 hours) |
| Molecular Weight | 166.2 Da (valproic acid) |
Adults: 1 tablet (500 mg sulfamethoxazole/80 mg trimethoprim) orally every 12 hours for 14 days.
| Dosage form | SOLUTION |
| Renal impairment | CrCl 15-30 mL/min: 50% of standard dose every 12 hours. CrCl <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment needed. Child-Pugh Class B or C: contraindicated. |
| Pediatric use | Children: 8 mg/kg/day trimethoprim and 40 mg/kg/day sulfamethoxazole divided every 12 hours. Maximum duration 14 days. |
| Geriatric use | Monitor renal function; reduce dose if CrCl <30 mL/min; avoid in elderly with folate deficiency. |
| 1st trimester | Avoid use due to risk of teratogenicity (neural tube defects, cardiovascular malformations) associated with valproate, a component of Prevduo. |
| 2nd trimester | Use only if benefit outweighs risk; valproate exposure may cause fetal harm including neural tube defects and developmental delays. |
| 3rd trimester | Avoid use; valproate increases risk of hemorrhagic syndrome in newborn (vitamin K deficiency) and withdrawal symptoms. |
Clinical note
Comprehensive clinical and safety monograph for PREVDUO (PREVDUO).
| Placental transfer | Valproate readily crosses the placenta with cord blood concentrations similar to maternal serum levels; extensive placental transfer documented. |
| Breastfeeding | Valproate is excreted into breast milk in low concentrations (1-10% of maternal serum levels). Monitor infant for potential adverse effects such as sedation, thrombocytopenia, and liver dysfunction. Weigh benefits of breastfeeding against minimal risk. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Pregnancy Category X. First trimester: high risk of skeletal and cardiac malformations (neural tube defects, cleft palate). Second and third trimesters: oligohydramnios, renal agenesis, pulmonary hypoplasia, intracranial hemorrhage, and fetal death. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function (serum creatinine, BUN), and electrolytes. Fetal ultrasound for growth restriction, amniotic fluid index, and anomalies. Nonstress test or biophysical profile after 24 weeks. |
| Fertility Effects | May impair fertility via endometrial atrophy and ovarian suppression; reversible discontinuation. |
■ FDA Black Box Warning
No FDA black box warnings are listed for Prevduo.
| Serious Effects |
Hypersensitivity to valproate or any componentHepatic disease or significant hepatic dysfunctionKnown urea cycle disordersPregnancy (for prevention of migraine) due to high teratogenic riskConcomitant use with topiramate (increased risk of hyperammonemia)
| Precautions | May cause tooth discoloration and enamel hypoplasia if used during tooth development (children <8 years), May cause photosensitivity; avoid excessive sunlight or UV exposure, Use caution in patients with hepatic impairment, May result in overgrowth of non-susceptible organisms including Clostridioides difficile, Potential for decreased efficacy with concomitant use of antacids, iron, or multivitamins, May cause dizziness or lightheadedness; caution when driving or operating machinery |
| Food/Dietary | Avoid grapefruit and grapefruit juice during treatment. No significant food interactions otherwise. |
| Clinical Pearls | PREVDUO (budesonide/glycopyrrolate/formoterol fumarate) is a fixed-dose triple therapy for COPD. Administer as two inhalations twice daily. No rescue use. Titrate to lowest effective dose. Monitor for pneumonia, oral candidiasis, and hypercortisolism. Use with caution in patients with severe hepatic impairment. Assess cardiovascular risk due to formoterol. |
| Patient Advice | Use exactly as prescribed; do not use for sudden symptoms. · Rinse mouth with water after each dose to prevent thrush. · Avoid exceeding two inhalations twice daily. · Report worsening symptoms or need for increased rescue inhaler use. · Notify healthcare provider of any vision changes, signs of infection, or adrenal insufficiency. |
Loading safety data…